Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Simultaneous inhibition of PFKFB3 and GLS1 selectively kills KRAS-transformed pancreatic cells.

Biochemical and biophysical research communications - 24 Sept 2021

Ozcan Selahattin C, Mutlu Aydan, Altunok Tugba H, Gurpinar Yunus, Sarioglu Aybike, Guler Sabire, Muchut Robertino J, Iglesias Alberto A, Celikler Serap, Campbell Paul M, Yalcin Abdullah

Abstract excerpt

Activating mutations of the oncogenic KRAS in pancreatic ductal adenocarcinoma (PDAC) are associated with an aberrant metabolic phenotype that may be therapeutically exploited. Increased glutamine utilization via glutaminase-1 (GLS1) is one such feature of the activated KRAS signaling that is essential to cell survival and proliferation; however, metabolic plasticity of PDAC cells allow them to adapt to GLS1...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Cell Proliferation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Survival

Share to Drug Screening Assays, Antitumor

Share to Glutaminase

Share to Pancreatic Neoplasms

Share to Proto-Oncogene Proteins p21(ras)

Share to Thiadiazoles

Source

Identifiers

PMID: 34325126
DOI: 10.1016/j.bbrc.2021.07.070

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Simultaneous inhibition of PFKFB3 and GLS1 selectively kills KRAS-transformed pancreatic cells.PMID 34325126Read ↗

KRAS: feeding pancreatic cancer proliferation.Semantic proximity Read ↗

Glutamine-restricted diets restore sensitivity to KRASG12D inhibitor through the reversal of ANXA1 mediated metabolic reprogramming.Semantic proximity Read ↗

p38γ MAPK Is Essential for Aerobic Glycolysis and Pancreatic TumorigenesisSemantic proximity Read ↗

Undermining Glutaminolysis Bolsters Chemotherapy While NRF2 Promotes Chemoresistance in KRAS-Driven Pancreatic Cancers.Semantic proximity Read ↗

Interplays of glucose metabolism and KRAS mutation in pancreatic ductal adenocarcinoma.Semantic proximity Read ↗

Compensatory metabolic networks in pancreatic cancers upon perturbation of glutamine metabolismSemantic proximity Read ↗

Oncogenic KRAS triggers metabolic reprogramming in pancreatic ductal adenocarcinomaSemantic proximity Read ↗

Netrin G1 promotes pancreatic tumorigenesis through cancer associated fibroblast driven nutritional support and immunosuppressionSemantic proximity Read ↗

KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective TreatmentSemantic proximity Read ↗

Metabolic reprogramming in KRAS-mutant cancers: Proven targetable vulnerabilities and potential therapeutic strategies.Semantic proximity Read ↗

Mutant GNAS drives pancreatic tumourigenesis by inducing PKA-mediated SIK suppression and reprogramming lipid metabolism.Semantic proximity Read ↗

Mutant KRAS Downregulates the Receptor for Leukemia Inhibitory Factor (LIF) to Enhance a Signature of Glycolysis in Pancreatic Cancer and Lung Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.